

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/699,580	10/30/2000	David H. Beach	GPCI-P10-019	8428
28120 75	590 03/15/2005	•	EXAM	INER
FISH & NEAVE IP GROUP			VIVLEMORE, TRACY ANN	
ROPES & GRAY LLP				
ONE INTERNATIONAL PLACE		ART UNIT	PAPER NUMBER	
BOSTON, MA 02110-2624			1635	

DATE MAILED: 03/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/699,580	BEACH ET AL.				
Office Action Summary	Examiner	Art Unit				
	Tracy Vivlemore	1635				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 27 D	1) Responsive to communication(s) filed on <u>27 December 2004</u> .					
2a) ☐ This action is FINAL . 2b) ☑ This	This action is FINAL . 2b)⊠ This action is non-final.					
,—	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) ☐ Claim(s) 29,37,41-43 and 45-47 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 29,37,41-43 and 45-47 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 6) Other:						

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Specification

The objection to the abstract of the disclosure is withdrawn in view of the amended abstract submitted December 27 2004.

Claim Rejections - 35 USC § 112

The rejections of record of claims 37, 39, 41-43 are withdrawn in view of applicant's amendments received December 27, 2004.

New Claim Rejections - 35 USC § 112

Claims 37, 39, 41-43 and 45-47 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the

Application/Control Number: 09/699,580

Art Unit: 1635

application was filed, had possession of the claimed invention. This is a new matter rejection.

Page 3

- 1. Claim 37 is directed to a method of inhibiting the transcription or translation of a polynucleotide encoding human CDC25A in a cell in vitro using an oligonucleotide that hybridizes to SEQ ID NO: 1 or the complement thereof. Claims 39 and 41-43 depend from claim 37 and recite further limitations describing the sequence and physical characteristics of the human CDC25A and characteristics of the polynucleotide being inhibited. Claim 45 is directed to a method of inhibiting the transcription or translation of a polynucleotide encoding human CDC25A in a cell in vitro using an oligonucleotide that is complementary to SEQ ID NO: 1 or a portion thereof which hybridizes to the polynucleotide or the complement thereof. Claims 46 and 47 depend from and limit claim 45 by further defining the nucleotide or amino acid sequence of the human CDC25A.
- 2. The specification does not provide support for oligonucleotides that hybridize to the complement of SEQ ID NO: 1 as recited in claim 37 and in claim 45 (ii).

 Additionally, the specification does not provide support for oligonucleotides that hybridize to SEQ ID NO: 1 or a portion thereof as recited in claim 45 (i). The sole disclosure in the specification of the claimed method appears at page 26, lines 3-10:

"In one embodiment, complex formation is prevented in an indirect manner, such as by preventing transcription and/or translation of the cdc25 DNA and/or RNA. This can be carried out by introducing into cells antisense oligonucleotides which hybridize to the cdc25-encoding nucleic acid sequences, and thus prevent their further processing."

This disclosure supports oligonucleotides that hybridize to the nucleic acid encoding CDC25A, but not to the complementary strand. This disclosure does not

Art Unit: 1635

provide support for hybridizing to a portion of SEQ ID NO: 1. No support for either of the limitations is present in the originally filed claims.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tracy Vivlemore whose telephone number is 571-272-2914. The examiner can normally be reached on Mon-Fri 8:45-5:15.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on 571-272-0760. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It

Art Unit: 1635

also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Tracy Vivlemore Examiner Art Unit 1635

TV March 7, 2005

> SEAN MCGARRY PRIMARY EXAMINER

1635